Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02546167 · ClinicalTrials.gov registry record · Phase 1
CART-BCMA Cells for Multiple Myeloma
A Phase 1 study, sponsored by University of Pennsylvania.
- Completed
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
NCT02546167: Completed Phase 1 study, sponsored by University of Pennsylvania.
NCT02546167 is a Phase 1 study that has completed, run by University of Pennsylvania. The registered enrollment target is 25 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02546167, a Phase 1 study, has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
Study Summary
Open-label, single-center, pilot study to assess the safety and feasibility of infusion of autologous T cells expressing BCMA (B-cell maturation antigen)-specific chimeric antigen receptors with tandem TCR and 4-1BB costimulatory domains (referred to as CART-BCMA ) in adult patients with multiple myeloma (MM). CART-BCMA cells will be given as a split dose intravenous infusion over 3 days. The duration of active intervention and monitoring is approximately 2 years.
Interventions
- BIOLOGICAL CART-BCMA
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2015-09-03 |
| Est. Completion | 2020-07-27 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02546167
The ClinicalTrials.gov registry entry for NCT02546167 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CART-BCMA is the first listed.
NCT02546167 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02546167 about?
NCT02546167 is a clinical study titled "CART-BCMA Cells for Multiple Myeloma". Open-label, single-center, pilot study to assess the safety and feasibility of infusion of autologous T cells expressing BCMA (B-cell maturation antigen)-specific chimeric antigen receptors with tandem TCR and 4-1BB costimulatory domains (referred to as CART-BCMA ) in adult patients with multiple my...
What is the current status of trial NCT02546167?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2015-09-03. Estimated completion is 2020-07-27.
What interventions are being tested in trial NCT02546167?
The interventions under investigation include: CART-BCMA (BIOLOGICAL).
Who is sponsoring clinical trial NCT02546167?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.